U.S. Markets closed

Incyte Corporation (INCY)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
114.87-2.22 (-1.90%)
At close: 4:00PM EDT

114.50 -0.37 (-0.32%)
After hours: 7:59PM EDT

People also watch
VRTXBMRNALXNREGNSGEN
Full screen
Previous Close117.09
Open117.63
Bid114.00 x 100
Ask114.50 x 8700
Day's Range114.63 - 118.61
52 Week Range83.01 - 153.15
Volume2,249,159
Avg. Volume1,352,318
Market Cap24.2B
Beta1.63
PE Ratio (TTM)-145.04
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study
    Zacks5 days ago

    Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study

    Eli Lilly and Company (LLY) and partner Incyte announced that baricitinib met its primary endpoint in a phase II study in people with moderate-to-severe atopic dermatitis.

  • Reuters6 days ago

    Lilly/Incyte pill beats placebo in mid-stage eczema trial

    Eli Lilly and Co and Incyte Corp on Thursday said a mid-stage trial of their oral drug baricitinib showed that at the highest dose it worked better than placebo for people with moderate-to-severe atopic dermatitis. The finding could be a boost for the drug's prospects, which suffered a setback earlier this year after U.S. regulators turned down an application for its use in rheumatoid arthritis, saying that more data was needed. Baricitinib, in a class of drugs known as Jak inhibitors, is sold in the European Union under the brand name Olumiant for treating rheumatoid arthritis.

  • Have Investors Already Priced In Incyte Corporation’s (INCY) Growth?
    Simply Wall St.6 days ago

    Have Investors Already Priced In Incyte Corporation’s (INCY) Growth?

    Today we’re going to take a look at the well-established Incyte Corporation (NASDAQ:INCY). The company’s stock See our latest analysis for INCY What is INCY worth? INCY appears to beRead More...